surmount-1 trial tirzepatide non-diabetic weight loss lowers body for adults with obesity, regardless of disease duration Effect of Tirzepatide on Maintenance
Description
In SURMOUNT-1, participants on 15mg achieved an average weight loss of 22.5%, approximately 52 pounds or 24 kilograms over 72 weeks
Compounded medications are prepared by licensed pharmacies and are not FDA-approved
ClinicalTrials.gov registration: NCT06659744, NCT07088718, NCT07096063
PBMs like CVS Caremark (the brand name of CVS PBM) typically negotiate discounts and rebates with drug manufacturers in exchange for preferred placement on formularies
Weight loss may be slower and less pronounced
The difference between 25 units and 35 units is much easier to see and draw accurately
